keynote-522: neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs place...
Published 4 years ago • 105 plays • Length 3:49Download video MP4
Download video MP3
Similar videos
-
5:25
neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early-...
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
9:16
keynote-522: pembro ct vs placebo ct neoadjuvant followed adjuvant pembro vs placebo in tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
4:24
comment: pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...
-
4:17
keynote-522: efs sensitivity & subgroup analyses
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
9:59
gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
-
34:12
keynote-522
-
7:15
pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembr...
-
0:57
a post hoc analysis of adjuvant radiation therapy in the keynote-522 study
-
6:52
immunotherapy added to chemotherapy improves pathological complete response in early triple nega...
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
2:53
neoadjuvant chemoimmunotherapy: keynote-522, i-spy & more